RightFit
RecruitingPhase 2

Ultralow Dose PET Imaging of 18F-Florbetapir, 18F-Flutemetamol

Evaluation of Ultralow Dose PET Imaging for Detecting Amyloid Tracer Uptake

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
18 Years to 120 Years
Sex
All sexes
Healthy volunteers
Accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

Not stated in the study description — ask the study team about visits and procedures.

Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This study tests a PET scan, a type of imaging test, to help find and track Alzheimer's disease, mild memory and thinking problems, and other types of dementia. It is for adults age 18 and older and aims to use 10 to 100 times less radiation than standard scans. Participants get an injection of a radioactive tracer called 18F-Florbetapir or 18F-Flutemetamol and have scans on a new, highly sensitive scanner for up to 3 hours.

The goal of this clinical trial is to evaluate an investigational ultralow dose Positron Emission Tomography (PET) imaging technique for Alzheimer's disease, mild cognitive impairment, other forms of dementia detection and monitoring. The main question it aims to answer is: Can the investigators optimize the timing, scan duration, and image reconstruction to reduce the radiation dose 10-100 fold of the current clinical standard? Participants will be injected with a radioactive tracer called Fluorine-18 (18F)-Florbetapir or 18F-Flutemetamol and be imaged on a new type of high-sensitivity PET scanner for up to 3 hours

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • Be age 18 or older.
  • Be able to understand and agree to join the study and follow study steps.
  • Not be pregnant or breastfeeding.
  • Have a negative pregnancy test if able to become pregnant.

Who can't join

  • Have gone over the yearly research radiation limit of 50 millisieverts (mSv), counting this study. Millisieverts measure radiation dose.
  • Have enrolled in this study more than four times before.
  • Have a severe fear of small spaces, long-term pain, or muscle, bone, or joint problems that prevent finishing the scan.
  • Be pregnant or breastfeeding.
  • Be unable to understand and agree to join the study.
  • Have any condition that the study doctor thinks could make the study unsafe for you or affect the study's results.

Simplified for readability. The official criteria below are what the study team uses.

Official eligibility criteria

Inclusion Criteria: Age ≥18 years; Ability to provide informed consent and comply with study procedures; For female participants: Must not be pregnant or breastfeeding; Negative pregnancy test required for women of childbearing potential. Exclusion Criteria: Participants who have exceeded NRC regulation for annual radiation exposure from prior research-related scans, including this study (50 millisievert \[mSv\] total); More than four prior enrollments in this study; Participants with severe claustrophobia, chronic pain, or musculoskeletal conditions that prevent completion of the PET scan; Pregnant or breastfeeding individuals (negative pregnancy test required); Inability to provide informed consent; Any condition that, in the investigator's judgment, may compromise participant safety or study integrity.

Study sites (1)

NJ